## Cytomegalovirus (CMV) infection and risk of mortality is cell transplantation (Allo-HSCT): A systematic review, manalysis

American Journal of Transplantation 19, 2479-2494 DOI: 10.1111/ajt.15515

**Citation Report** 

#	Article	IF	CITATIONS
1	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. Biology of Blood and Marrow Transplantation, 2020, 26, 972-977.	2.0	11
2	Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial. Experimental Hematology and Oncology, 2020, 9, 5.	2.0	3
3	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. American Journal of Transplantation, 2021, 21, 258-271.	2.6	11
4	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplantation, 2021, 56, 1281-1290.	1.3	3
5	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Preâ€ŧransplant predictors of survival, reactivation, and spontaneous clearance. Transplant Infectious Disease, 2021, 23, e13548.	0.7	7
6	The impact of viral infections on the results of hemopoietic stem cell transplantation in patients with hematologic malignancies. Jurnal Infektologii, 2021, 12, 85-92.	0.1	1
7	Parental limited English proficiency in pediatric stem cell transplantation: Clinical impact and health care utilization. Pediatric Blood and Cancer, 2021, 68, e29174.	0.8	5
8	Cytomegalovirusâ€specific Tâ€cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. British Journal of Haematology, 2021, 195, 637-641.	1.2	4
10	Epstein–Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non–Hodgkin lymphoma: the prevalence and impacts on outcomes. Annals of Hematology, 2021, 100, 2773-2785.	0.8	6
11	Oral shedding of herpesviruses and clinical outcomes in hematopoietic stem cell transplant patients. Oral Diseases, 2023, 29, 815-826.	1.5	0
12	Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. Clinical Pharmacology and Therapeutics, 2022, 111, 485-495.	2.3	1
13	The Relationship between Conditioning Regimen with Viral and Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Hematology Research, 0, 8, 53-56.	0.5	0
14	Association Between Cytomegalovirus and Epstein-Barr Virus Co-Reactivation and Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2022, 12, 818167.	1.8	6
16	Immunoprofiling reveals cell subsets associated with the trajectory of cytomegalovirus reactivation post stem cell transplantation. Nature Communications, 2022, 13, 2603.	5.8	8
17	Features of Epstein–Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen. Frontiers in Cellular and Infection Microbiology, 2022, 12, .	1.8	3
18	Risk factors and incidence of cytomegalovirus viremia and disease in pediatric patients with allogeneic hematopoietic <scp>stem cell</scp> transplantation: An 8â€year singleâ€center experience in Latin America. Pediatric Transplantation, 0, , .	0.5	1
19	Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2022, 24, .	0.7	2
20	Herpesvirus Screening in Childhood Hematopoietic Transplant Reveals High Systemic Inflammation in Episodes of Multiple Viral Detection and an EBV Association with Elevated IL-11², IL-8 and Graft-Versus-Host Disease. Microorganisms, 2022, 10, 1685.	1.6	3

#	Article	IF	CITATIONS
21	Early diagnostic value of liver stiffness measurement in hepatic sinusoidal obstruction syndrome induced by hematopoietic stem cell transplantation. World Journal of Clinical Cases, 2022, 10, 9241-9253.	0.3	1
22	Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children's patients following allogeneic hematopoietic stem cell transplantation: A retrospective single-center study. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
23	Current management of CMV infection in cancer patients (solid tumors). Epidemiology and therapeutic strategies. Revista Espanola De Quimioterapia, 2022, 35, 74-79.	0.5	4
24	Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered?. Cells, 2022, 11, 3463.	1.8	2
25	New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT. Bone Marrow Transplantation, 2023, 58, 203-208.	1.3	13
26	An impact of CMV and HHV-6 reactivation on the course of early period after hematopoietic stem cell transplantation in patients with hematologic malignancies. Jurnal Infektologii, 2023, 14, 41-50.	0.1	1
27	Cardiovascular morbidity following conventional therapy versus allogeneic hematopoietic stem cell transplantation after childhood, adolescent, and young adult leukemia in Finland. International Journal of Cancer, 2023, 152, 2292-2302.	2.3	1
29	Cytomegalovirus Diseases in Hematopoietic Cell Transplant Recipients. , 2023, , 141-160.		0

32 Cytomegalovirus Vaccines. , 2023, , 258-274.e9.